Advanced in Prostate Cancer

Dr. Dwight E. Heron

Radiation Oncology
Mercy Health Physicians Youngstown Specialty Care LLC
8401 Market St, 
Boardman, OH 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Advanced in Prostate Cancer
Mercy Health Physicians Youngstown Specialty Care LLC
8401 Market St, 
Boardman, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dwight Heron is a Radiation Oncologist in Boardman, Ohio. Dr. Heron is rated as an Advanced provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Prostate Cancer, Lung Cancer, Pancreaticoduodenectomy, and Prostatectomy. Dr. Heron is currently accepting new patients.

His clinical research consists of co-authoring 189 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles and participated in 2 clinical trials in the study of Prostate Cancer.

Specialties
Radiation Oncology
Licenses
Radiology in PA
Hospital Affiliations
St Elizabeth Youngstown Hospital
Hmhp St Elizabeth Boardman Health Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
SummaCare
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

MERCY HEALTH PHYSICIANS YOUNGSTOWN SPECIALTY CARE LLC
8401 Market St, Boardman, OH 44512
Other Locations
NEO UROLOGY ASSOCIATES INC
6262 Mahoning Ave, Suite C, Austintown, OH 44515

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc)
Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc)
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Radiation
Study Drugs: Cyclophosphamide, Mesna, Rituximab, Alemtuzumab, Thiotepa, GM-CSF, Intravenous immunoglobulin
Study Phase: Phase 2
A Randomized, Phase II Study of Definitive Radiotherapy With Concurrent Cisplatin vs. Docetaxel-cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma: an ERCC1 Biomarker Enrichment and Interaction Design
A Randomized, Phase II Study of Definitive Radiotherapy With Concurrent Cisplatin vs. Docetaxel-cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma: an ERCC1 Biomarker Enrichment and Interaction Design
Enrollment Status: Recruiting
Publish Date: March 26, 2025
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Docetaxel, Cetuximab
Study Phase: Phase 2
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
Utilization of Low Level Laser Therapy for Radiation Induced Dermatitis in Patients With Head and Neck Squamous Cell Carcinoma
Utilization of Low Level Laser Therapy for Radiation Induced Dermatitis in Patients With Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: June 27, 2025
Intervention Type: Device
Study Phase: Not Applicable
Phase II Study Determining the Efficacy of Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases
Phase II Study Determining the Efficacy of Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases
Enrollment Status: Completed
Publish Date: June 26, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
PHASE I STUDY OF FRACTIONATED STEREOTACTIC RADIOSURGERY FOR LARGE BRAIN METASTASES
PHASE I STUDY OF FRACTIONATED STEREOTACTIC RADIOSURGERY FOR LARGE BRAIN METASTASES
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
A Phase I Study of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases
A Phase I Study of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Radiation
Study Phase: Not Applicable
Prospective Evaluation Of Hypofractionated Stereotactic Body Radiotherapy For Low And Intermediate Risk Prostate Cancer
Prospective Evaluation Of Hypofractionated Stereotactic Body Radiotherapy For Low And Intermediate Risk Prostate Cancer
Enrollment Status: Completed
Publish Date: May 02, 2024
Intervention Type: Radiation
Study Phase: Not Applicable
Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation
Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation
Enrollment Status: Terminated
Publish Date: October 11, 2023
Intervention Type: Radiation, Drug
Study Phase: Phase 2
Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cetuximab, Docetaxel
Study Phase: Phase 2
Phase II Study of Stereotactic Radiosurgery for Patients With Oligo-recurrent Disease
Phase II Study of Stereotactic Radiosurgery for Patients With Oligo-recurrent Disease
Enrollment Status: Completed
Publish Date: May 19, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase II Prospective Trial of Low-Level Laser Therapy for Prevention of Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
A Phase II Prospective Trial of Low-Level Laser Therapy for Prevention of Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
Enrollment Status: Completed
Publish Date: April 13, 2022
Intervention Type: Device
Study Phase: Not Applicable
Induction Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma A Prospective Evaluation in Patients With Locally Advanced Pancreas Cancer
Induction Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma A Prospective Evaluation in Patients With Locally Advanced Pancreas Cancer
Enrollment Status: Completed
Publish Date: March 08, 2022
Intervention Type: Drug, Radiation
Study Phase: Phase 2
Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Device, Drug
Study Drug: Cetuximab
Study Phase: Phase 2
A Prospective, Randomized Phase II Study of Surgery With or Without Adjuvant Stereotactic Body Radiotherapy (SBRT) in Patients With Previously-Irradiated Head and Neck Cancer
A Prospective, Randomized Phase II Study of Surgery With or Without Adjuvant Stereotactic Body Radiotherapy (SBRT) in Patients With Previously-Irradiated Head and Neck Cancer
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Radiation
Study Phase: Not Applicable
SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma A Prospective Evaluation in Select Patients With Resected Pancreas Cancer
SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma A Prospective Evaluation in Select Patients With Resected Pancreas Cancer
Enrollment Status: Completed
Publish Date: November 24, 2021
Intervention Type: Radiation
Study Phase: Not Applicable
Chemotherapy (Paclitaxel and Carboplatin)and Thoracic Radiotherapy With Swallowed Manganese Superoxide Dismutase (MnSOD) Plasmid Liposome Protection in Patients With Locally Advanced Stage III Non-Small Cell Lung Cancer: A Phase I-II Study
Chemotherapy (Paclitaxel and Carboplatin)and Thoracic Radiotherapy With Swallowed Manganese Superoxide Dismutase (MnSOD) Plasmid Liposome Protection in Patients With Locally Advanced Stage III Non-Small Cell Lung Cancer: A Phase I-II Study
Enrollment Status: Terminated
Publish Date: November 12, 2021
Intervention Type: Drug, Genetic, Radiation
Study Phase: Phase 1/Phase 2
Measuring the Effect of Radiation Therapy on Patient Activity Levels
Measuring the Effect of Radiation Therapy on Patient Activity Levels
Enrollment Status: Terminated
Publish Date: August 09, 2018
View 18 Less Clinical Trials

189 Total Publications

Recurrent Squamous Cell Carcinoma of the Head & Neck: Novel Approaches to Re-Irradiation.
Recurrent Squamous Cell Carcinoma of the Head & Neck: Novel Approaches to Re-Irradiation.
Journal: Otolaryngologic clinics of North America
Published: September 30, 2025
Similar Doctors
Elite in Prostate Cancer
Dr. Daniel E. Spratt
Radiation Oncology
Elite in Prostate Cancer
Dr. Daniel E. Spratt
Radiation Oncology

University Hospitals Medical Group Inc

11100 Euclid Ave, 
Cleveland, OH 
 (60.5 miles away)
216-844-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Spratt is a Radiation Oncologist in Cleveland, Ohio. Dr. Spratt is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bone Tumor, Prostatectomy, and Orchiectomy. Dr. Spratt is currently accepting new patients.

Elite in Prostate Cancer
Dr. Jay P. Ciezki
Radiation Oncology
Elite in Prostate Cancer
Dr. Jay P. Ciezki
Radiation Oncology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (61.0 miles away)
Experience:
37+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jay Ciezki is a Radiation Oncologist in Cleveland, Ohio. Dr. Ciezki has been practicing medicine for over 37 years and is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Cholangiocarcinoma (Bile Duct Cancer), Prostatectomy, and Atherectomy.

Elite in Prostate Cancer
Dr. Rahul D. Tendulkar
Radiation Oncology
Elite in Prostate Cancer
Dr. Rahul D. Tendulkar
Radiation Oncology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (61.0 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rahul Tendulkar is a Radiation Oncologist in Cleveland, Ohio. Dr. Tendulkar is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Breast Cancer, Familial Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Prostatectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Heron's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile